The Australian Genomic Cancer Medicine Centre (AGCMC) is an ecosystem involving federal and state governments, cancer treatment centres, basic and translational research institutes, patients and industry, working together to:
Improve the quality of life and survival of cancer patients through nationally co-ordinated, collaborative, research-led, evidence-based care, grow the health economy through greater engagement with industry, innovate clinical trial designs and pathology platforms that anticipate the future of precision medicine in health care and establish early detection and risk stratification based on personalised risk of cancer.
Rapid advances in scientific knowledge mean that research is now the standard of care.
Mark Wainwright has more than 25 years’ experience as chairand board member of co-operative ventures in the higher education and industry sectors including numerous co-operative research centres. Prior to accepting the position of AGCMC Chair,Mark was the Vice-Chancellor and President of the University of New South Wales(UNSW Sydney). He holds a DSc by Research from the University of South Australia, a PhD from McMaster University in Ontario, Canada, as well as aMAppSc in Chemical Engineering and a BAppSci in Applied Chemistry from the University of AdelaideHe is the chair of Intersect Australia Pty Ltd, and the Sydney School of Entrepreneurship. He is also a director of AARNet Pty Ltd. He is a member of International Advisory Board among along list of distinguished board memberships, external committees, institutes and societies in Australia and overseas.
Founder and CEO, Rare Cancers Australia, Richard attended the University of Melbourne where he studied maths and statistics. He then trained as an Actuary but was seduced by the fledgling IT industry before qualifying. After several years working in software development, Richard formed his own software company which he then sold in 1990 before embarking on a second software venture in Europe. In 1996, Richard returned to Australia where he was retained by an American company to establish a sales channel in Australia. In 2001 Richard left the IT industry and worked in a number of not-for-profits associated with retail, politics and health. In 2012, Richard and his wife Kate established Rare Cancers Australia, a patient advocacy group whose mission is to improve the lives and outcomes for rare cancer patients
Prof Thomas is the Chief Executive Officer of the Australian Genomic Cancer Medicine Centre, Head of Cancer Research at Garvan and Director of The Kinghorn Cancer Centre, a collaboration between Garvan and St Vincent’s Hospital,Sydney. An NHMRC Principal Research Fellow, David is an oncologist with a particular focus on the impact of genomics on cancer medicine and public health. David is the originator of Garvan’s Genomic Cancer Medicine Program that brings together researchers and clinicians to translate research findings into the clinic. His work has had significant translational impact leading to a new therapeutic option for patients with advanced bone disease. He established a national infrastructure for clinical research into sarcomas, the Australasian Sarcoma Study Group. As Director of the statewide adolescent and young adult cancer service, onTrac@PeterMac, he played a significant role in the development of adolescent and young adult oncology. Professor Thomas is the current President of the Connective Tissue Oncology Society, the peak organisation in his field. Despite an active clinical role, Professor Thomas has published more than 160 research papers, including senior orlead author papers in Molecular Cell, Journal of Cell Biology, Cancer Cell, Journal of Clinical Investigation, Journal of Clinical Oncology, Lancet Oncology, and JAMA Oncology. His H index is 47.
Paul Jeans has been Chancellor of the University of Newcastle since 2013. Until his retirement in 2000,in a career spanning 42 years, he held senior roles in BHP where he was Executive General Manager/CEO of BHP’s Ferrous Minerals Business and earlier three of its Steel Businesses, which included responsibility for both Newcastle and Port Kembla Steelworks. His earlier career focused on engineering and he rose to become General Manager of BHP Engineering. Paul has led manufacturing, mining, logistics and technical services businesses through periods of growth, significant change and efficiency improvement, major capital expansion and international operation. He has been chair of the Newcastle Port Corporation,Orinoco Iron CA, Associated Airlines, World Marine and General Insurances and sixBHP subsidiary companies. Paul has also been a Director of Foster’s Brewing Group, Energy Australia, Ausgrid and five BHP subsidiary companies.
Head of the Immunogenomics Laboratory, Bill and Patricia Ritchie Foundation Chair and Conjoint Professor at UNSW Sydney in the St Vincent’s Clinical School (Faculty of Medicine), Chris Goodnow is an internationally renowned immunologist. Chrishas had an extensive international research career and has been a faculty member at Stanford University and the Australian National University, and has been closely involved in several biotechnology start-up companies. He joined Garvan in 2015 and he is best known for integrating molecular genetics and genomics with immunology, for which he has received numerous awards and election to the Australian Academy of Science,the UK Royal Society, and the US National Academy of Science.
Bruce Goodwin’s career with the Johnson & Johnson family of companies spans 35 years. He has been in General Management roles for the last ten years including two terms in his current role of Managing Director Janssen Australia and New Zealand, and also three years as President and Representative Director Janssen Japan. Prior to General Management he has held Management Board Director positions in Sales and Marketing and in Finance, as well as having gained valuable experience in Global Licensing and Acquisitions. Hisservice with Johnson & Johnson outside of his home country, Australia,includes postings to Janssen Japan, Janssen Belgium and Janssen United Kingdom.Bruce is a respected Industry Leader and is currently an elected Director and Board Member of Medicines Australia, a role he has also held previously. Whilst in Japan he served as the Vice Chair of the Japan Based Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA). Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines and in 2017 he was a key member of the Cancer Drugs Access Committee. Bruce Goodwin holds an Economics degree from Macquarie University and an MBA from Macquarie Graduate School of Management, and is a Graduate Member of the Australian Institute of Company Directors (GAICD).
Professor Simes, Director, NHMRC Clinical Trials Centre (CTC) and Sydney Catalyst Translational Research Centre, is a leading international researcher in clinical trials, particularly in cancer, cardiovascular disease, diabetes and neonatal medicine. As Senior Principal Research Fellow and Director of the NHMRC CTC, University of Sydney, he leads a team of 200 who collaborate nationally and internationally to improve health practice and health outcomes through better use of clinical trials research. His work has had a significant impact on current knowledge and clinical practice. He practices as a medical oncologist in neuro-oncology.
Professor North is Director of the Murdoch Children’s Research Institute and the David Danks Professor of Child Health Research at the University of Melbourne. She is a national and international leader in genomic medicine. In 2014, she was appointed as Co-Chair of the Global Alliance for Genomics and Health - a collaborative network of more than 500 organisations from more than 45 countries, funded by the NIH and the Wellcome Trust. From 2016 she had led the Australian Genomics Health Alliance, an NHMRC-funded national network of more than 80 institutions whose mission is to provide evidence and practical strategies for the implementation of genomic medicine in the health system. In 2012, Professor North was appointed Chair of the NHMRC Research Committee and in 2014 was appointed a Foundation Fellow of the Australian Academy of Health and Medical Science. She chairs the International Advisory Board of the Great Ormond Street Institute of Child Health (UK) and is a member of the Board of the Victorian Comprehensive Cancer Centre. In recognition of her eminent service to genomic medicine nationally and internationally, to medical research in the fields of genetics, neurology and child health, and as a mentor and role model, she was awarded a Companion (AC) of the Order of Australia in 2019.
Professor Brown is Director of the Cancer Clinical Trials Unit at Royal Adelaide Hospital, Adelaide, Australia. He head sits melanoma research program and chairs its fortnightly melanoma multidisciplinary meeting. He is a senior consultant medical oncologist in the Royal Adelaide Hospital Cancer Centre. Professor Brown sub specialises in the care of patients with advanced melanoma or lung cancer. His clinical research is focused mainly on facilitating rapid access to new targeted therapies and on early phase clinical trials for testing new immunotherapies for the treatment of melanoma and lung cancer. His laboratory research is focused mainly on understanding better how to direct T cells toward cancer targets. Professor Brown has published 119 papers, including 17 in high impact journals (Lancet,Lancet Oncology, Nature Medicine, Cell, Blood, Clin Cancer Res, Oncogene, AnnOncology, J Nucl Med) and has an H index of 30.
Professor Johnstone is a cancer researcher who has utilized genetic mouse models of hemopoietic malignancies and solid tumors to understand the epigenetic changes that underpin tumor onset and progression and to develop new therapies that target epigenetic and transcriptional regulatory proteins. Professor Johnstone has recently discovered how epigenetic based-agents can engage the host immune system to drive prolonged therapeutic responses. Professor Johnstone and his team areadvancing these fundamental discoveries to clinical testing through the implementation of clinical trials that combine epigenetic and immunotherapeutic agents. Professor Johnstone has published a total of 227 papers with >25,000 total citations and a H-index of 74.
Paul is an Associate Professor at The University of Sydney and lectures in banking and risk management. He is also currently Company Secretary of Intersect Australia Limited and the Sydney School of Entrepreneurship Limited. Paul has over twenty years’ experience in the banking industry having worked for a number of banking organisations, including Advance Bank of Australia, the Australian Financial Markets Association, Hong kong Bank of Australia Limited (HSBC), Australian Bank Limited and the Commonwealth Banking Corporation. He was previously Chief Financial Officer and Company Secretary of The Securities Industry Research Centre of Asia-Pacific (SIRCA),and was responsible for all aspects of the Company’s management and operating functions, including liaison with SIRCA’s key industry partners; the ASX, the Sydney Futures Exchange, the Australian Financial Markets Association and Thomson Reuters.